Jazz Pharmaceuticals plc (J7Z) - Net Assets
Based on the latest financial reports, Jazz Pharmaceuticals plc (J7Z) has net assets worth €4.53 Billion EUR (≈ $5.30 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€11.86 Billion ≈ $13.87 Billion USD) and total liabilities (€7.33 Billion ≈ $8.57 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Jazz Pharmaceuticals plc's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €4.53 Billion |
| % of Total Assets | 38.22% |
| Annual Growth Rate | 10.55% |
| 5-Year Change | 8.91% |
| 10-Year Change | 130.04% |
| Growth Volatility | 14.71 |
Jazz Pharmaceuticals plc - Net Assets Trend (2013–2025)
This chart illustrates how Jazz Pharmaceuticals plc's net assets have evolved over time, based on quarterly financial data. See Jazz Pharmaceuticals plc (J7Z) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Jazz Pharmaceuticals plc (2013–2025)
The table below shows the annual net assets of Jazz Pharmaceuticals plc from 2013 to 2025. For live valuation and market cap data, see Jazz Pharmaceuticals plc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €4.32 Billion ≈ $5.05 Billion |
+5.49% |
| 2024-12-31 | €4.09 Billion ≈ $4.79 Billion |
+9.55% |
| 2023-12-31 | €3.74 Billion ≈ $4.37 Billion |
+21.11% |
| 2022-12-31 | €3.09 Billion ≈ $3.61 Billion |
-22.18% |
| 2021-12-31 | €3.97 Billion ≈ $4.64 Billion |
+8.35% |
| 2020-12-31 | €3.66 Billion ≈ $4.28 Billion |
+17.64% |
| 2019-12-31 | €3.11 Billion ≈ $3.64 Billion |
+12.82% |
| 2018-12-31 | €2.76 Billion ≈ $3.22 Billion |
+1.63% |
| 2017-12-31 | €2.71 Billion ≈ $3.17 Billion |
+44.52% |
| 2016-12-31 | €1.88 Billion ≈ $2.19 Billion |
+17.43% |
| 2015-12-31 | €1.60 Billion ≈ $1.87 Billion |
+16.59% |
| 2014-12-31 | €1.37 Billion ≈ $1.60 Billion |
+5.84% |
| 2013-12-31 | €1.30 Billion ≈ $1.51 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jazz Pharmaceuticals plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3386.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €646.18 Million | 14.96% |
| Other Components | €3.67 Billion | 85.04% |
| Total Equity | €4.32 Billion | 100.00% |
Jazz Pharmaceuticals plc Competitors by Market Cap
The table below lists competitors of Jazz Pharmaceuticals plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Jefferies Financial Group Inc
NYSE:JEF
|
$11.87 Billion |
|
Nantong Jianghai Capacitor Co Ltd
SHE:002484
|
$11.87 Billion |
|
Penske Automotive Group Inc
NYSE:PAG
|
$11.88 Billion |
|
Ecopro BM. Co. Ltd
KQ:247540
|
$11.89 Billion |
|
Trimble Inc
NASDAQ:TRMB
|
$11.84 Billion |
|
Dynatrace Holdings LLC
NYSE:DT
|
$11.83 Billion |
|
AVIC Jonhon Optronic Technology Co Ltd
SHE:002179
|
$11.81 Billion |
|
Industrivarden AB ser. A
ST:INDU-A
|
$11.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jazz Pharmaceuticals plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,093,756,000 to 4,318,584,000, a change of 224,828,000 (5.5%).
- Net loss of 356,148,000 reduced equity.
- Share repurchases of 125,023,000 reduced equity.
- Other factors increased equity by 705,999,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-356.15 Million | -8.25% |
| Share Repurchases | €125.02 Million | -2.89% |
| Other Changes | €706.00 Million | +16.35% |
| Total Change | €- | 5.49% |
Book Value vs Market Value Analysis
This analysis compares Jazz Pharmaceuticals plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.78x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.31x to 2.78x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €45.30 | €195.15 | x |
| 2018-12-31 | €47.95 | €195.15 | x |
| 2019-12-31 | €55.41 | €195.15 | x |
| 2020-12-31 | €65.15 | €195.15 | x |
| 2021-12-31 | €64.60 | €195.15 | x |
| 2022-12-31 | €48.81 | €195.15 | x |
| 2023-12-31 | €60.03 | €195.15 | x |
| 2024-12-31 | €67.52 | €195.15 | x |
| 2025-12-31 | €70.30 | €195.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jazz Pharmaceuticals plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.25%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8.35%
- • Asset Turnover: 0.37x
- • Equity Multiplier: 2.70x
- Recent ROE (-8.25%) is below the historical average (9.32%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 16.70% | 24.79% | 0.39x | 1.73x | €86.76 Million |
| 2014 | 4.26% | 4.98% | 0.35x | 2.44x | €-78.73 Million |
| 2015 | 20.61% | 24.87% | 0.40x | 2.08x | €169.67 Million |
| 2016 | 21.14% | 26.67% | 0.31x | 2.56x | €209.10 Million |
| 2017 | 17.98% | 30.14% | 0.32x | 1.89x | €216.54 Million |
| 2018 | 16.21% | 23.64% | 0.36x | 1.89x | €171.36 Million |
| 2019 | 16.82% | 24.21% | 0.39x | 1.78x | €212.27 Million |
| 2020 | 6.52% | 10.10% | 0.36x | 1.79x | €-127.36 Million |
| 2021 | -8.31% | -10.65% | 0.25x | 3.10x | €-726.19 Million |
| 2022 | -7.26% | -6.12% | 0.34x | 3.51x | €-532.63 Million |
| 2023 | 11.10% | 10.82% | 0.34x | 3.05x | €41.13 Million |
| 2024 | 13.68% | 13.77% | 0.34x | 2.93x | €150.74 Million |
| 2025 | -8.25% | -8.35% | 0.37x | 2.70x | €-788.01 Million |
Industry Comparison
This section compares Jazz Pharmaceuticals plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $2,614,309,982
- Average return on equity (ROE) among peers: -42.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jazz Pharmaceuticals plc (J7Z) | €4.53 Billion | 16.70% | 1.62x | $11.86 Billion |
| PROQR THERAPEUTICS EO-04 (0PQ) | $66.68 Million | -96.62% | 1.57x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $201.16 Million | -11.05% | 0.06x | $171.71 Million |
| PreveCeutical Medical Inc (18H) | $-2.29 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $4.10 Billion | -7.20% | 0.11x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $39.63 Million | -145.12% | 5.94x | $1.10 Billion |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.58 Million | -6.53% | 0.28x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
| BioNTech SE (22UA) | $20.25 Billion | 4.60% | 0.14x | $20.05 Billion |
About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC)… Read more